TALS Stock Overview
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Talaris Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.20 |
| 52 Week High | US$32.90 |
| 52 Week Low | US$8.90 |
| Beta | 2.18 |
| 1 Month Change | -5.88% |
| 3 Month Change | -11.69% |
| 1 Year Change | 91.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.26% |
Recent News & Updates
Recent updates
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?
May 24
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?
Feb 14We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Oct 21Talaris drops 24% after patient death in late-stage trial for lead asset
Oct 20Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Aug 29Talaris Therapeutics GAAP EPS of -$0.44
Aug 15We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Jul 06Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
Jun 30Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans
Mar 23Talaris Therapeutics EPS beats by $0.49
Jun 14Shareholder Returns
| TALS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.9% | -3.6% | -2.4% |
| 1Y | 91.5% | -2.6% | 23.4% |
Return vs Industry: TALS exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: TALS exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| TALS volatility | |
|---|---|
| TALS Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TALS has not had significant price volatility in the past 3 months.
Volatility Over Time: TALS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 84 | Mary Fenton | talaristx.com |
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients.
Talaris Therapeutics, Inc. Fundamentals Summary
| TALS fundamental statistics | |
|---|---|
| Market cap | US$553.16m |
| Earnings (TTM) | -US$74.77m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs TALS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TALS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$74.77m |
| Earnings | -US$74.77m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TALS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/21 11:43 |
| End of Day Share Price | 2023/10/19 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Talaris Therapeutics, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Evercore ISI |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |